Table 1 Baseline characteristics
Variables | Total | Antegrade (n = 73) | Retrograde (n = 43) | P-value |
|---|---|---|---|---|
Age, mean (SD) | 64.03 ± 11.1 | 64.04 ± 10.7 | 64.02 ± 12.78 | 0.862 |
Male, n (%) | 88 (75.8) | 55 (82.1) | 33 (82.5) | 0.864 |
Stroke history, n (%) | 28 (24.1) | 21 (28.7) | 9 (20.3) | 0.352 |
MI history, n (%) | 22 (18.9) | 12 (16.4) | 8 (18.6) | 0.766 |
Diabetes, n (%) | 37 (31.8) | 24 (32.8) | 10 (23.3) | 0.273 |
CAD, n (%) | 49 (42.2) | 28 (38.4) | 21 (48.8) | 0.273 |
Hypertension, n (%) | 74 (63.7) | 50 (68.5) | 24 (55.8) | 0.171 |
Dyslipidemia, n (%) | 47 (40.5) | 31 (42.5) | 16 (37.2) | 0.578 |
CHF, n (%) | 13 (11.2) | 8 (11.0) | 5 (11.6) | 0.912 |
Smoking, n (%) | 42 (36.2) | 29 (39.7) | 12 (27.9) | 0.198 |
EGFR, mean (SD) | 83.6 ± 13.02 | 84.55 ± 13.0 | 81.99 ± 13.07 | 0.793 |
CLI, n (%) | 69 (59.4) | 45 (61.6) | 24 (55.8) | 0.537 |
ALI, n (%) | 19 (16.3) | 12 (16.4) | 7 (16.3) | 0.982 |
Rutherford 3, n (%) | 28 (24.1) | 16 (21.9) | 12 (27.9) | 0.446 |
Rutherford 4–6, n (%) | 88 (75.8) | 57 (78.1) | 31 (72.1) | 0.446 |
ABI, mean (SD) | 0.27 ± 0.21 | 0.25 ± 0.21 | 0.29 ± 0.22 | 0.005 |
Aspirin (n) | 57 (49.1) | 38 (52.1) | 19 (44.2) | 0.413 |
Clopidogrel (n) | 22 (18.9) | 17 (23.3) | 5 (11.6) | 0.122 |
Statin (n) | 37 (31.8) | 23 (31.5) | 14 (32.6) | 0.907 |